Summary:
A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Qualified Participants Must:
• Be male-female 18-75 years old
•
Have biopsy-confirmed MASH (NASH) with Stage 2 or Stage 3 fibrosis within 6 months. If no current biopsy is available, see below for additional criteria that must be met to qualify for study.***
•
Have BMI between 25-50
•
Have Increased liver enzymes
•
Not have history or presence of any other liver disease
•
Not have history or presence of cirrhosis
•
Not have history or presence of HIV
•
Not have history *or presence of* any other uncontrolled medical conditions
•
Not have history of bariatric surgery within past 5 years
•
Not have history of malignancy within 5 years
Qualified Participants May Receive:
$100 per completed visit, and all tests/physical exams/imaging studies (MRI, Fibroscan, Liver Biopsy)/medical care for study indication at no cost.